B-RAF V600E ͉ hypothemycin ͉ irreversible kinase inhibitor ͉ Michael adduct R esorcylic acid lactones (RALs) are polyketide natural products with a large macrocyclic ring fused to resorcylic acid. Some RALs contain an ␣,␤-unsaturated ketone in the macrocycle, as exemplified by the cis-enone RALs hypothemycin, 5Z-7-oxozeaenol, and L-783,277 (Fig. 1) . The cis-enone RALs have been shown to inhibit mammalian cell proliferation and tumor growth in animals (1-3). Furthermore, several reports have indicated that cis-enone RALs inhibit certain protein kinases, such as mitogenactivated protein (MAP) kinase (MAPK) kinase (MEK)1 (4), TGF-␤-activated kinase 1 (TAK1) (5) and platelet-derived growth factor receptor (PDGFR) (6), but not others, such as RAF, PKA, PKC, endothelial growth factor receptor (EGFR), FGF receptor, ZAP70, MEK kinase 4, and lymphoid-specific Tyr kinase p56kk (LCK) (3, 4, 6). Where tested, targets inhibited by the cis-enone RALs were not affected by trans-enone RALs or RAL analogs lacking the ␣,␤-unsaturated ketone (4, 5).
R
esorcylic acid lactones (RALs) are polyketide natural products with a large macrocyclic ring fused to resorcylic acid. Some RALs contain an ␣,␤-unsaturated ketone in the macrocycle, as exemplified by the cis-enone RALs hypothemycin, 5Z-7-oxozeaenol, and L-783,277 (Fig. 1) . The cis-enone RALs have been shown to inhibit mammalian cell proliferation and tumor growth in animals (1-3). Furthermore, several reports have indicated that cis-enone RALs inhibit certain protein kinases, such as mitogenactivated protein (MAP) kinase (MAPK) kinase (MEK)1 (4), TGF-␤-activated kinase 1 (TAK1) (5) and platelet-derived growth factor receptor (PDGFR) (6), but not others, such as RAF, PKA, PKC, endothelial growth factor receptor (EGFR), FGF receptor, ZAP70, MEK kinase 4, and lymphoid-specific Tyr kinase p56kk (LCK) (3, 4, 6) . Where tested, targets inhibited by the cis-enone RALs were not affected by trans-enone RALs or RAL analogs lacking the ␣,␤-unsaturated ketone (4, 5) .
L-783,277 was shown to be a potent in vitro inhibitor of MEK1, competitive with ATP, that became even more potent upon preincubation (4) . The apparent time-dependent inhibition caught our attention because it is a hallmark of affinity-directed covalent bond formation between enzyme and inhibitor, and the ␣,␤-unsaturated ketone moiety is an effective Michael acceptor of protein nucleophiles, particularly Cys thiolate.
Off-target inhibition by a kinase inhibitor is usually unpredictable, and assessment of complete specificity usually requires screening of the entire kinome (7) . In the present work, we identified a Cys residue that is conserved in the ATP site of kinase targets reported to be inhibited by cis-enone RALs but absent from those that are not. Furthermore, a structure-bioinformatics approach revealed that this Cys is present in a subset of some 46 protein kinases in the kinome that include such important targets as mitogen receptor Tyr kinases, MEK, and ERK. We show that hypothemycin forms stable covalent adducts with this Cys residue and is highly efficacious in inhibiting growth of cells dependent on the target kinases, in particular, cells dependent on mitogen receptor RAL targets or harboring B-RAF V600E mutations that drive the ERK pathway.
Results
Bioinformatics. Sequence alignment of the kinases reported to be inhibited by cis-enone RALs revealed a conserved Cys residue (Cys-166 in human ERK2) adjacent to the completely conserved Asp that is involved in binding the Mg 2ϩ complexed to ATP; kinases that were reportedly not inhibited by a RAL had no Cys residue at that position. Interrogation of the human kinome sequence database revealed that some 46 of 510 identified kinases contained the target Cys and were therefore considered candidates for RAL inhibition (Table 1) .
Of the 46 Cys-containing RAL targets, 38 exist in 8 evolutionarily related clusters, 7 of which lie within 5 major branches of the human kinase tree ( Fig. 2) (8) . The largest branch of Ϸ90 Tyr kinases contains a cluster of 7 RAL targets, all in the subbranch composed of the 12 split kinases associated with mitogen-stimulated cell proliferation; these include all three vascular EGFRs (VEGFRs) and four of five PDGFR-type kinases. In the branch containing the 74 calmodulin-dependent protein kinases and related kinases, 10 of the 11 RAL targets are concentrated in 2 clusters. Seven RAL targets are in a group of 11 MAPK substrates and consist of the 4 ribosomal subunit kinase (RSK) isoforms, two MAPK-interacting kinase 1͞2 isoforms, and MAPK-activating protein 5; the remainders are the three protein kinase D members and SPEG (striated muscle preferentially expressed gene). In the 61-membered CMGC branch, three clusters and one isolate make up 12 of the Cyscontaining RAL targets; these include all five CDKL (cyclindependent kinase-like) isoforms, four members of the MAPK branch, including ERK1͞2, the two glycogen synthase kinase (GSK)3 isoforms, and the isolate PRP4K (pre-mRNA processing factor 4 kinase). The 47 STE kinases include 8 targets: one cluster of 7 MEK isoforms and 1 isolate. Among the 43 Tyr kinase-like kinases are three isolates, including TAK1 and TGF-␤ receptor type 2. Target kinases not belonging to the seven major branches include a cluster of three in the AAK1͞BIKE͞GAK (adaptorassociated kinase 1͞bone morphogenetic protein 2-inducible kinase͞cyclin G-associated kinase) group and three isolates. Two large branches of the tree, the 63 AGC and the 12 CK1 (casein kinase 1) kinases, are free of Cys-containing RAL targets.
We also attempted to address whether other kinases and ATPbinding proteins might have the target Cys; however, most of these have different crystallographic folds than the Ser͞Thr͞Tyr-protein kinases, making predictions of RAL sensitivity difficult. However, there are at least three homology families [ATM͞PIK3C͞PIK4C (ataxia telangiectasia mutated͞phosphatidylinositol kinase 3C͞ phosphatidylinositol kinase 4C), IPK (inositol polyphosphate kinase), and CHK͞EK (cholin kinase͞ethanolamine kinase) of human kinases that have a similar fold to that of the standard protein kinases, and none of these has a Cys at the equivalent position as in the putative RAL targets.
Kinase Screen. Hypothemycin was screened against a panel of 124 kinases (Upstate Cell Signaling Solutions, Dundee, U.K.) containing 19 putative Cys-containing RAL targets (see Table 4 , which is published as supporting information on the PNAS web site). After an initial screen with 0.20 M hypothemycin, the Cys-containing targets and enzymes inhibited Ն20% were rescreened with 2.0 M hypothemycin. With the exception of GSK3␣, all of the putative Cys-containing targets were inhibited by 60-100% in one or both screens. Three kinases, cSRC, TRKA, and TRKB, lacking the target Cys residue, were also inhibited.
Enzyme Kinetics. Affinity-directed covalent enzyme inactivation involves formation of a reversible complex with dissociation constant K i , followed by a first-order loss of enzyme activity with rate constant k inact . Analogous to k cat ͞K m , the k inact ͞K i is the second-order rate constant for covalent bond formation under dilute conditions (i.e., [I] and [E] Ͻ Ͻ K i ) and reflects a ''specificity constant'' for the reaction of the inhibitor with the enzyme (Scheme 1) (9) .
A sensitive, continuous fluorometric assay that measures ADP formation ‡ was used to determine kinetic parameters of a variety of kinases (see Table 5 , which is published as supporting information on the PNAS web site); progress curves of the reaction in the presence of various concentrations of the inhibitor were generated and analyzed to assess inhibition kinetics (see Fig. 3 , which is published as supporting information on the PNAS web site) (10). Table 2 shows the inhibition constants for hypothemycin against a number of kinases, including, where relevant, k inact and t 1/2 values for time-dependent inactivation.
GSK3␤, one of the putative hypothemycin targets, was poorly inhibited in the initial screen and showed a high K i and consequent low k inact ͞K i . The fact that k inact is as rapid as for most other kinases tested suggests that once the weak reversible complex is formed, the acceptor enone and nucleophilic Cys are suitably juxtaposed for covalent bond formation. GSK3␣ is the single Cys-containing target studied that did not show time-dependent inhibition by hypothemycin.
Although cSRC, TRKA, and TRKB showed inhibition by hypothemycin in the single-point screening assay described above, they do not contain the target Cys for Michael adduct formation. E ϩ I L | ; hypothemycin showed competitive inhibition with respect to ATP but did not show time-dependent inactivation. Likewise, hypothemycin showed reversible but not time-dependent inhibition of ERK2 C166A, in which the target Cys is replaced with Ala (data not shown).
Interaction of Hypothemycin with ERK2.
In addition to enzyme kinetics, several other approaches verified an affinity-directed mechanism for covalent adduct formation between hypothemycin and the Cys-containing ERK2.
Reversible binding and thiol reactivity are necessary for potent inhibition.
The small thiol-reactive reagents cyclohex-2-enone and 5,6-dihydro-2H-pyran-2-one react with thiols 18-and 4-fold faster, respectively, than hypothemycin (see below) but do not inhibit ERK2 at 1 mM over a period of 60 min, indicating that reversible binding is required for effective covalent inactivation. Disruption of the cis-enone system by reduction of the double bond to give 7Ј8Ј-dihydro-hypothemycin gave a reversible inhibitor with K i of 100
M that did not show time-dependent inhibition of ERK2, demonstrating the necessity of a Michael acceptor for potent inhibition. Reactivity of Hypothemycin with Thiols. As a model for nonspecific reactions, hypothemycin and certain analogs were treated with various concentrations of thiols at pH 7.5, and aliquots were analyzed by HPLC over time for remaining hypothemycin. Secondorder rate constants of thiolate anion with hypothemycin were 3.6 Ϯ 0.1 M Ϫ1 ⅐s Ϫ1 for 2-mercaptoethanol (pK a ϭ 9.5) and 6.6 Ϯ 0.1 M Ϫ1 ⅐s Ϫ1 for glutathione (pK a ϭ 8.75). Second-order rate constants for reaction of cyclohex-2-enone and 5,6-dihydro-2H-pyran-2-one with 2-mercaptoethanol thiolate showed rate constants of 65 and 14.2 M Ϫ1 ⅐s Ϫ1 , respectively. MV4-11 and EOL1 (see Fig. 4 , which is published as supporting information on the PNAS web site); with P815, phosphorylated MEK (P-MEK) and ERK (P-ERK) levels were too low to detect. As with SU11248 (11), MV4-11 (an AML cell line with the FLT3-ITD mutation) was Ͼ100-fold more sensitive to hypothemycin than an AML cell line with wild-type FLT3 (IC 50 ϭ 0.72 M). Hypothemycin was also approximately equipotent with either BAY43-9006 or SU11248 in growth inhibition of the VEGFRdependent human umbilical vein endothelial cell line; Western analysis with VEGF-stimulated human umbilical vein endothelial cells demonstrated complete inhibition of VEGFR, MEK1͞2, and ERK1͞2 phosphorylation.
Inhibition of RAL Targets in Cells.
Analyses of the NCI60 cell line and gene mutation data (12, 13) show that seven of the eight cell lines most sensitive to hypothemycin (National Cancer Institute Developmental Therapeutics Program no. NSC#354462) harbor the activating B-RAF V600E mutation. To extend these results, six additional B-RAF V600 mutants were tested (Table 3 ; see also Table 6 , which is published as supporting information on the PNAS web site) and found to be Ϸ15-to 300-fold more sensitive to hypothemycin than were A549 and SKOV-3 cells that have an active ERK pathway and wild-type B-RAF. Furthermore, hypothemycin was on average Ϸ85-fold (range 15-to 200-fold) more potent against B-RAF V600E mutants than the RAF inhibitor BAY43-9006, although the inhibitors are equipotent against A549 and SKOV-3 cells. Treatment of cells with hypothemycin for 1 h resulted in a concentration-dependent depletion of P-ERK1͞2, an expected consequence of MEK1͞2 inhibition. With the B-RAF V600E mutants, HT29 and COLO829, IC 50 values for P-ERK1͞2 depletion were 20 and 10 nM hypothemycin, respectively, which were significantly lower than the values of 300 and 600 nM for A549 and SKOV3, respectively (data not shown).
The time necessary for inhibition of the ERK pathway was determined by incubation of cells with 1 M hypothemycin and analysis of extracts for P-ERK1͞2 at various times. With the non-B-RAF mutants SKOV-3 and A549, it took 30-60 min before significant depletion of P-ERK1͞2 was observed, whereas with the B-RAF V600E mutant cell lines HT29 and COLO829, P-ERK1͞2 levels were depleted within 10 min (see Fig. 5 , which is published as supporting information on the PNAS web site). We also examined the duration of ERK pathway inhibition after removal of the drug. Cells were treated with 1 M of hypothemycin or the reversible MEK inhibitor U0126 for 1 h to deplete cells of P-ERK1͞2, washed to remove free drug, and P-ERK1͞2 levels monitored with time. With the reversible MEK inhibitor U0126, P-ERK1͞2 levels in both B-RAF V600E mutant HT29 and B-RAF wild-type cell lines A549 recovered to control levels by the first time point examined (3 h) after removal of the drug. In contrast, with hypothemycin, there was prolonged depletion of P-ERK1͞2 after treatment: In the B-RAF wild-type A549 cell line, P-ERK1͞2 was easily detectable 3 h after drug removal and recovered by Ϸ6 h; in HT29, a B-RAF V600E mutant cell line, P-ERK1͞2 was barely detectable even 24 h after drug removal (see Fig. 5 ).
Because hypothemycin has a long duration of action, we examined whether a brief daily exposure was sufficient to inhibit B-RAF V600E-dependent cell growth. Approximately 10 6 HT29 or COLO829 cells were exposed daily for 1 h to 2 M hypothemycin or 10 M U0126, and viable cells were counted on day 4. Whereas cells in the UO126-treated and control samples grew to equal numbers, hypothemycin-treated cells remained the same as originally seeded.
We also tested whether hypothemycin would inhibit stimulated activation of the p38 and JNK͞SAPK (c-Jun N-terminal kinase͞ stress-activated protein kinase) cascades, because p38 cascade contains the RAL targets TAK1 and MEK3͞6, and JNK͞SAPK cascade contains MEK4͞7. Treatment of HT29 cells with 20 ng͞ml phorbol 12-myristate 13-acetate (PMA) for 30 min resulted in high activation of p38. When cells were pretreated with 1 M hypothemycin for 1 h, the PMA-stimulated phosphorylation of the MEK3͞6 substrate p38 was prevented; similar pretreatment with the MEK1͞2 inhibitor U01216 had no effect on p38 phosphorylation. Likewise, treatment of HeLa cells with 1 M hypothemycin for 1 h inhibited phosphorylation of the TAK1 substrate IB kinase ␤, induced by treatment with 10 ng͞ml IL-1 for 15 min. Finally, treatment of A549 cells with 1 M hypothemycin for 1 h completely prevented phosphorylation of the MEK 4͞7 substrate JNK͞SAPK induced by treatment with 20 ng͞ml PMA for 30 min (see Fig. 4 ). As controls, 72-h exposure of all cell lines tested to 7Ј8Ј-dihydrohypothemycin showed IC 50 values Ն100 M, indicating requirement for the cis-enone moiety of hypothemycin for cytotoxicity and kinase inhibition.
Discussion
We identified a Cys residue that is conserved in the ATP site of Ser͞Thr͞Tyr protein kinases reported to be inhibited by cis-enone RALs but absent from those that are not. The target Cys (Cys-166 in human ERK2) is immediately N-terminal to the completely conserved Asp that binds Mg 2ϩ -ATP and is present in a subset of 46 of the Ϸ510 protein kinases. Because the enone moiety of RALs is susceptible to Michael addition, we speculated that the inhibition by RALs results from affinity-directed covalent adduct formation with the conserved Cys residue.
The 46 putative targets for cis-enone RALs represent Ϸ9% of the known Ser͞Thr͞Tyr kinases in the human kinome. Although this at first appears to be a large number of targets, it may be small compared with other kinase inhibitors of current interest. For example, BAY-43-9006 and SU11248, two multikinase inhibitors currently in clinical trials, have submicromolar K i values on some 16% and 47%, respectively, of the Ϸ120 kinases assayed (7). Furthermore, in contrast to scattered profiles of kinases inhibited by leads obtained by random screening, the RAL targets are clustered in eight evolutionarily and functionally related groups. For example, in the branch of the some 90 Tyr kinases, all seven RAL targets are found in the subbranch containing the 12 mitogen receptor split kinases. Likewise, there are clusters of targets that encompass all of the MEK MAPK kinases, the ERK group, and certain groups downstream of ERK, such as the entire ribosomal subunit kinase group. In effect, the 46 individual RAL targets condense to major subsets of related targets that encompass multiple components of important pathways.
Initially, hypothemycin was screened as an inhibitor against a panel of some 124 kinases, 19 of which contained the conserved Cys. The RAL inhibited 18 of the 19 targeted Cys kinases and only three of the other kinases tested.
We investigated the kinetics of hypothemycin inhibition of 13 of the Cys-containing RAL targets. With the exception of GSK3␣, all putative targets showed time-dependent inactivation consistent with initial formation of a reversible enzyme-inhibitor complex, followed by covalent Michael adduct formation. Additional evidence for the mechanism was obtained with experiments using ERK2, a kinase that has been notoriously resistant to inhibitor design. First, reagents that are more reactive toward thiols than hypothemycin but do not reversibly bind to ERK2 do not inhibit the enzyme. Second, the ERK2-[ 3 H]hypothemycin complex was stable toward denaturation and isolable during SDS͞PAGE. Third, dissociation of the ERK2-hypothemycin complex is extraordinarily slow (Ͼ24 h), a feature in accord with covalent inactivation. Fourth, trypsin digestion of ERK2-hypothemycin complexes yielded the expected active-site peptide containing the inhibitor attached to the target Cys-166. Finally, a crystal structure of the ERK2-hypothemycin complex showed covalent attachment of the 8Ј-carbon of the inhibitor to Cys-166 of the protein (our unpublished results).
The kinetic parameters for hypothemycin differed significantly for different Cys-containing target kinases that showed timedependent inhibition: There was a Ϸ10 4 -fold range in K i for reversible binding, a Ϸ5-fold range in k inact , and a Ϸ10 5 -fold range in k inact ͞K i . The wide range of k inact ͞K i values suggests that specificity of inhibition of certain kinases within the targeted subset might be achieved by controlling the exposure time; here, kinases such as MEK1 and the VEGFRs that have high k inact ͞K i values would be inactivated by low concentrations of a RAL earlier than those with low reaction rates.
Curiously, the weak reversible complexes of hypothemycin with GSK3␣ and GSK3␤ had K i values Ϸ10 2 -to 10 4 -fold higher than for the other targets examined. The peptide backbone between ␤-strand 4 and ␣-helix D of ERK2 contains Met-106 and is tightly packed against the aromatic ring of the inhibitor. In contrast, GSK3␣ and GSK3␤ have no corresponding Met but rather a Pro, and the region has six to nine additional residues not found in closely related kinases. We speculate that this region may serve as a selectivity filter (14) that accounts for reversible binding differences and that, within the weak GSK3␣-hypothemycin complex, the cis-enone of the inhibitor is not suitably juxtaposed with the target Cys to form a covalent bond.
Kinetic analysis of the three kinases that were inhibited in the screen but do not contain the RAL targeted Cys residue (cSRC, TRKA, and TRKB) revealed that these enzymes are reversibly inhibited by hypothemycin but do not form covalent adducts although each contains a Cys residue in the ATP site that is remote from the RAL target Cys.
An important question is whether the RALs are sufficiently specific for their targets to be useful in a biological environment that contains free thiols and other thiol-containing proteins (15) . At saturating concentrations of the inhibitor, covalent bond formation is limited by the first-order rates of inactivation. Depending on the enzyme, these rates occur with t 1/2 values of 2-12 min, probably reflecting the positioning and proximity of the enone to the target Cys. At low concentrations of enzyme and inhibitor, k inact ͞K i reflects a second-order rate constant for covalent adduct formation. The reaction is very fast, with most target kinases showing k inact ͞K i values that exceed their k cat ͞K m and are some 10 5 -to 10 7 -fold greater than the second-order rate constants for the reaction of hypothemycin with thiols. Furthermore, kinases that contain Cys in different positions of their ATP sites than the target kinases, e.g., cSRC, TRKA, TRKB, PLK3, and NEK2, do not form covalent adducts with hypothemycin. Thus, the reaction of hypothemycin with most of its targets is significantly faster than with naturally occurring small thiols (e.g., glutathione) or, most important, other thiol-containing proteins.
We anticipated that hypothemycin would be a potent inhibitor of cancer cell lines dependent on ERK pathway-activating kinase mutants that are molecular targets of RALs given that it inhibits most mitogen receptor kinases and uniquely inhibits both the downstream MAPK kinases (MEK1͞2) and the MAPKs (ERK1͞ 2). Cell lines carrying activating mutations in the mitogen receptors c-KIT, FLT3, or PDGFR␣ (all RAL targets) were inhibited by hypothemycin as effectively as by the potent receptor kinase inhibitors BAY43-9006 and SU11248. As expected, growth inhibition by hypothemycin correlated with inhibition of autophosphorylation of the receptor kinase and with phosphorylation of the downstream MEK1͞2 and ERK1͞2.
The ERK pathway-activating B-RAF V600E mutation is found in Ϸ60% of melanomas, Ϸ20% of colon cancers, and Ϸ2% of breast cancers (14) . As initially indicated in the NCI60 cell panel screen and expanded upon here, hypothemycin is selectively potent against all tested melanoma, colon, and breast cancer cell lines having the ERK pathway-activating B-RAF V600E mutation. As reported for the potent MEK inhibitors CI-1040 and PD0325901 (16) , hypothemycin inhibits such cells more effectively than those having an active ERK pathway absent the B-RAF mutation (e.g., activating RAS mutants) or the RAF inhibitor BAY43-9006. Solit et al. (16) have suggested that selectivity of MEK inhibitors for B-RAF mutants may be due to the selective decline in cyclin D that occurs upon inhibition of the ERK pathway in such cells. The ''ultrasensitive'' cooperative response of the ERK cascade (17) may also contribute to hypothemycin's potency for B-RAF V600E cells. It has been shown that, whereas RAF exhibits hyperbolic MichaelisMenten kinetics, the MEK and ERK enzymes behave cooperatively with Hill-coefficients of Ϸ2 and 5, respectively; hence, the downstream effects of the pathway should be most profound by inhibition of ERK pathway enzymes in the order ERK Ͼ MEK Ͼ RAF (15) . Therefore, it is anticipated that RAF inhibitors, such as BAY43-9006, should not be particularly effective against such cells, and, although MEK inhibitors are effective, dual MEK͞ ERK inhibitors such as the cis-enone RALs should be superior. Indeed, in the NCI60 screen, B-RAF V600E cells are on average Ϸ23-fold more sensitive to hypothemycin than cells with RAS mutations, whereas there is just a 3-fold difference with the specific MEK inhibitor PD98059. An additional attractive feature of the RALs for inhibition of B-RAF V600E cells is that the onset of intracellular inhibition of MEK is rapid (Ϸ10 min), and the duration is long (Ϸ24 h); in cells with an active ERK pathway absent the B-RAF mutation, the onset of inhibition is longer and the duration is shorter. As expected, in preliminary experiments hypothemycin showed excellent activity in inhibiting a B-RAF V600E melanoma xenograft (our unpublished results).
Hypothemycin also was a potent inhibitor of VEGFR, was approximately equipotent with BAY43-9006 and SU11248 in inhibiting growth of VEGF-dependent human umbilical vein endothelial cells (HUVEC), and inhibited phosphorylation of VEGFR, MEK1͞2, and ERK1͞2 in these cells. Finally, we showed that pretreatment with hypothemycin prevented stimulated phosphorylation of the MEK3͞6 substrate p38, the MEK4͞7 substrate JNK͞SAPK, and the TAK1 substrate IB kinase ␤.
The RALs join a small but growing number of kinase inhibitors that function by affinity-directed covalent inactivation that includes inhibitors of phosphatidylinositol 3-kinase (18), EGFR (19) , and certain Cys-containing members of the ribosomal subunit kinase family (14) . The common prejudice against irreversible inhibitors is belied by the fact that 19 of the 71 enzyme targets of marketed drugs are covalently modified by the drug (20) . Indeed, provided that target selectivity in a biological environment can be achieved, such inhibitors offer several potential advantages over reversible binding agents. First, the onset of covalent inhibition is a function of time and inhibitor concentration, so selectivity within the target subset might be altered by duration of exposure. Second, the reaction is thermodynamically driven toward the covalent adduct, and high concentrations of inhibitor are not needed to achieve effective inhibition. Third, once covalently bound, such inhibitors do not readily dissociate from the enzyme, and restoration of enzyme activity requires new synthesis. Fourth, as shown for EGFR, irreversible inhibition can circumvent drug resistance (21) . Finally, with sufficient exposure, they are infinitely potent inhibitors that exceed the efficacy of reversible inhibitors.
Materials and Methods
Materials. Rat ERK2 was expressed in E. coli, purified and activated as reported (22) . Other kinases were obtained from Upstate Cell Signaling Solutions or Invitrogen and experiments used the manufacturer's specifications of purity and concentration. Hypothemycin and 7Ј,8Ј-dihydrohypothemycin were isolated from Hypomyces subiculosus (23 Table 5 ) and various amounts of inhibitor (Ϸ0.01-100 M final concentration) in 10 mM Tris, pH 7.5. Fluorescence was monitored at 530:590 nm (excitation͞emmission) in 30-sec intervals for 30 min at ambient temperature. Reversible competitive inhibition was analyzed by measuring changes in initial velocity with SOFTMAXPRO software. For time-dependent inactivation, product versus time curves were fitted (PRISM 4.0b, Graphpad, San Diego), to the equation [P] ϭ (v i ͞k obs )⅐(1 Ϫ exp(Ϫk obs ⅐t)), where P is the product formed at time t, v i is the initial velocity, and k obs is the apparent first-order rate constant for enzyme inactivation (10) . The data were then fitted to the equation
, where K app is the apparent dissociation constant of the reversible enzyme-inhibitor complex and k inact is the first-order rate constant for apparent irreversible conversion of the enzyme-inhibitor complex to covalently bound complex (10) . K i values were calculated from K i ϭ K app ͞(1 ϩ [ATP]͞K mATP ) by using experimentally determined K m values for ATP (see Table 5 ). GBq) and 2.2 M inactive or active ERK2 in binding buffer [20 mM Mops-KOH, pH 7.4͞50 mM KCl͞10 mM MgCl 2 ͞0.1 mM EDTA͞2 mM tris(2-carboxyethyl)phosphine hydrochloride] were incubated at ambient temperature for 50 min. Twenty microliters of 1.0 mM unlabeled hypothemycin was added to give a final concentration of 100 M. Aliquots of 20 l were electrophoresed at various times by SDS͞PAGE. The gel was dried, exposed to a Tritium storage phosphor screen, and scanned on a Typhoon imager (Molecular Devices).
Cytotoxicity Assays. Cell lines were from American Type Culture Collection (Manassas, VA) or Deutsche Sammlung von Mikroorganismen Zellkulturen (Braunschweig, Germany) and grown according to the suppliers' recommendations. Cells were plated into the 96-well microtiter plates at 4,000 cells per well, incubated overnight at 37°C, and then treated with various drug concentrations. After 72 h, cells were counted with the Cell Titer Glo Luminescent Cell Viability Assay kit (Promega).
Phosphoprotein Analysis. Cell lines were grown to 70% confluency in recommended media supplemented with 10% FBS in 6-cm dishes. Inhibitors or DMSO (vehicle control) were added, and the plates were incubated at 37°C for the desired incubation time. For lysis of adherent cells, media was removed and cells were rinsed with PBS. Cells were lysed in 0.3 ml of supplemented radioimmunoprecipitation assay (RIPA) buffer (see Fig. 4 ) on ice and scraped. The lysate was passed through a 21-gauge syringe needle three times, and cell debris was removed by centrifugation at 15,000 ϫ g for 10 min at 4°C. For nonadherent cells, cells were harvested by centrifugation at 193 ϫ g for 10 min and washed with 5 ml of PBS. The cell pellet was lysed in 0.3 ml of RIPA buffer and treated as described above. Protein concentrations were normalized to Ϸ1 mg͞liter before addition of 4ϫ protein sample buffer, boiling, and electrophoresis on 4-12% Bis-Tris gels (Invitrogen). Gels were blotted semidry to poly(vinylidene difluoride) membranes. Membranes were blocked and incubated with antibodies to visualize total and phosphorylated kinases by following the instructions of the manufacturers.
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